The Apparent Effects of Ziprasidone on Plasma Lipids and Glucose
J Clin Psychiatry 2001;62(5):347-349
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: We examined the effects of
ziprasidone on body mass index (BMI) and serum levels of glucose,
cholesterol, and triglycerides.
Method: As part of a multicenter study examining
different strategies for switching to ziprasidone from other
antipsychotics, we evaluated weight and serum glucose,
cholesterol, and triglyceride measurements at baseline and
following 6 weeks on ziprasidone treatment in 37 patients at our
Results: Short-term treatment with ziprasidone
appeared to lead to significant reduction in serum cholesterol (p
< .001) and triglyceride levels (p = .018) independent of
changes in BMI. Ziprasidone treatment appeared to have no
significant effect on BMI or glucose level, perhaps due to the
small number of subjects.
Conclusion: Ziprasidone appears to independently
lead to a lowering of serum lipid levels.